Faruqi & Faruqi, LLP Announces Investigation of K-V Pharmaceutical Company
Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and enforcement of federal antitrust laws, is investigating potential wrongdoing at K-V Pharmaceutical Company (“K-V” or the “Company”) (NYSE: KV-A) (NYSE: KV-B). Faruqi & Faruqi, LLP seeks to determine whether certain officers and directors at K-V violated federal securities laws in connection with statements made to the Company's shareholders.
The investigation focuses on whether certain individuals violated federal securities laws by, among other things, failing to disclose that: (1) the Company had inaccurately claimed that the Food and Drug Administration (the “FDA”) was granting K-V the exclusive distribution rights over “Makena,” a drug used to prevent miscarriages; (2) the FDA would not be enforcing K-V’s rights by preventing the Company’s competitors from distributing generic formulations of the drug; and (3) the drug’s $1,500 price would reduce the availability of Makena to low-income and other at-risk groups.
On March 30, 2011, the FDA revealed that it did not intend to take enforcement action against K-V’s competitors for distributing generic versions of K-V’s Makena.
If you purchased K-V securities between February 14, 2011 and April 4, 2011 and you would like to discuss your legal rights, visit www.faruqilaw.com/KV. You can also contact us by calling Anthony Vozzolo or Richard W. Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com or firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding K-V's conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.